BioMarin to Participate in Upcoming Investor Conferences
Get Alerts BMRN Hot Sheet
Join SI Premium – FREE
- Stifel Healthcare Conference,
November 11 at3:20 pm EST - UBS Global Biopharma Conference,
November 16 at9:20 am GMT - Jefferies Global Healthcare Conference,
November 17 at11:30 am GMT
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
|
Contacts: |
|
|
Investors |
Media |
|
|
|
|
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
|
(415) 455-7558 |
(650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-upcoming-investor-conferences-302928633.html
SOURCE BioMarin Pharmaceutical Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $94 at Oppenheimer
- Astemo Plans $11 Million Investment in its Muncie Manufacturing Operations
- 'FOOD TRUTH: HOW ULTRA-PROCESSED FOOD DESTROYED OUR HEALTH AND HOW TO MAKE FOOD A FORCE FOR GOOD' BY PETER CASTLEMAN TO BE RELEASED WORLDWIDE NOV. 10
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Stifel, UBS, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share